A

Accuray

Robotics-assisted, image-guided radiotherapy for cancer

Clinical Success Manager - UK & Ireland

Full-Time
No salary listed
Mid
Remote in UK
RemoteTravel within the assigned territory may reach 50%.
Sales & Account ManagementAccount Management

About the job

Requirements
  • Strong clinical background in radiotherapy, oncology, medical physics, or a related field.
  • Proven experience in a customer-facing role with commercial exposure, such as sales or account management.
  • Demonstrated ability to drive business within an installed base and develop new opportunities.
  • Excellent communication and presentation skills, with the ability to convey complex concepts in a compelling way.
  • Ability to build relationships, influence stakeholders, and create customer trust.
  • Ability to work proactively with a high level of autonomy and accountability.
  • Hands-on experience with the complete product portfolio.
  • Fluency in the local languages of the regions covered.
  • Ability to travel up to 50% of the time within the assigned territory.
Responsibilities
  • Own and develop installed-base accounts as the primary point of contact to improve long-term customer success and satisfaction with the solutions.
  • Build and maintain long-term, trust-based relationships with clinical, technical, and executive stakeholders to secure potential future TITU.
  • Collaborate with Product Development, Marketing, Training, Clinical Applications and Physics Support, and Service to maintain high-quality communication and disseminate customer and prospective-customer feedback.
  • Act as a bridge between customers and internal clinical, service, marketing, and operations teams to ensure seamless execution and high customer satisfaction, including successful first-in-country product implementations.
  • Drive installed-base revenue growth through upgrades, service offerings, and new business opportunities within existing customers.
  • Support the full sales cycle from opportunity identification to deal closure in collaboration with regional business, business management, and regional service leaders during trade-in and trade-up deals, and assist with service purchases, contract negotiations, and renewals.
  • Conduct customer visits and co-deliver presentations and demonstrations that translate complex solutions into clear clinical and business value.
  • Support workshops and on-site engagements that reinforce clinical excellence and strengthen customer partnerships.
  • Identify and escalate customer needs, challenges, competitive developments, and market insights to shape strategy and offerings.
  • Act as a liaison between key opinion leaders and the company medical affairs team, providing feedback and insights on market trends and customer needs.
  • Record customer interactions and projects in the customer relationship management system.
  • Maintain up-to-date expertise to deliver customer guidance.
  • Attend key meetings and trade shows, including ESTRO, to strengthen brand presence, capture market insights, and develop new prospect relationships.

About the company

Accuray provides cancer-care technology that uses robotics and image guidance to deliver precise, non-invasive radiation treatments. Its flagship CyberKnife system places a robotic arm around the patient to aim highly focused radiation beams at tumors anywhere in the body, performing radiosurgery without surgery. In 2011 it expanded its product line by acquiring TomoTherapy, adding a helical radiation therapy platform to its portfolio, broadening the ways clinicians can treat cancer. The company differentiates itself by combining robotics with real-time imaging to track tumors and adjust treatment in real time, and by offering a broader, multi-product radiation oncology system rather than a single device. Accuray’s goal is to provide effective, non-invasive cancer treatments to patients worldwide, growing its global installed base and advancing access to precise radiation therapy.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Madison, Wisconsin

Founded

1990

Get referred to Accuray

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 transformation delivered over $20 million in cost and margin improvements.
  • Q4 fiscal 2026 service revenue rose 6%, supporting margins despite product weakness.
  • September 2026 Samsung NeuroLogica collaboration expands CyberKnife imaging ambitions before commercial launch.

What critics are saying

  • Fiscal 2026 revenue fell 12% to $401.9 million; product revenue dropped 27%.
  • Accuray withdrew fiscal 2026 guidance in May 2026 after Middle East shipment delays.
  • TCW's covenant holiday ends December 2027; another sales slump risks lender-controlled restructuring.

What makes Accuray unique

  • CyberKnife delivers robotic radiosurgery with sub-millimeter precision across body tumors since 2001.
  • Fiscal 2026 services supplied 57% of revenue, creating recurring installed-base economics.
  • UW-Madison's 10-year collaboration and Samsung NeuroLogica partnerships deepen Accuray's technology ecosystem.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Third News
Oct 6th, 2026
Accuray stockholders approve $60M financing deal and board expansion

Accuray Incorporated announced stockholders approved all proposals at its 6 October 2026 special meeting, advancing a strategic financing agreement with TCW Asset Management Company LLC, its primary lender and major shareholder. The July 2026 deal converts $40 million of term loan debt into convertible preferred stock and includes a $15 million equity investment from TCW. Accuray also gains access to a delayed draw term loan of up to $5 million and relief from certain financial covenants until 31 December 2027. Approved measures include issuing common stock under Nasdaq rules, increasing authorised shares, and implementing a reverse stock split with a ratio between 1-for-15 and 1-for-40. The company also announced governance enhancements and board expansion.

Market Chameleon
Sep 28th, 2026
Accuray (ARAY) highlights Samsung NeuroLogica volumetric imaging collaboration for CyberKnife as shares jump during market hours.

Accuray (ARAY) highlights Samsung NeuroLogica volumetric imaging collaboration for CyberKnife as shares jump during market hours. 28 September 2026, 9:55 AM The collaboration aims to bring more volumetric imaging information into the treatment room, but no product has been announced. Accuray Incorporated (NASDAQ:ARAY) said it has entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp. ("Samsung NeuroLogica") to pursue advanced volumetric imaging capabilities for the CyberKnife System. The announcement coincided with the American Society of Radiation Oncology (ASTRO) Annual Meeting in Boston, where the companies are highlighting their collaboration. Accuray framed the effort as part of a broader strategy of targeted partnerships - pairing Samsung NeuroLogica's experience in mobile CT and volumetric imaging with Accuray's strengths in precision treatment delivery, robotic radiosurgery, and motion management. Importantly for investors, the company said the work will proceed through phased development and evaluation and that no commercial product offering has been announced.

Business Insider
Sep 27th, 2026
Accuray, Samsung NeuroLogica advance volumetric imaging collaboration.

Accuray, Samsung NeuroLogica advance volumetric imaging collaboration. Sep. 27, 2026, 11:25 AM Accuray Incorporated (ARAY) announced that it had entered into agreements with Samsung HME America (SSNLF) to pursue advanced volumetric imaging capabilities for the CyberKnife System. The announcement coincides with the American Society of Radiation Oncology, ASTRO, Annual Meeting in Boston, Massachusetts, where the companies are highlighting their collaboration. The collaboration represents another example of Accuray's strategy to address customer priorities through targeted partnerships that bring together complementary expertise. Published first on TheFly - the ultimate source for real-time, market-moving breaking financial news. Try Now>> Read More on ARAY:

Yahoo Finance
Aug 20th, 2026
Accuray secures $55M financing, cuts costs by $20M amid China headwinds and tariff uncertainty

Accuray Incorporated reported fiscal 2026 results, describing the year as foundational for streamlining operations and reducing costs. Geopolitical tensions and tariff uncertainty in China contributed to approximately $58 million in product revenue decline. The company achieved $20 million in cost and margin improvements, exceeding its initial $12 million target. Service revenue grew 6% in Q4, driven by strategic pricing and an expanding installed base. Accuray is pivoting to a partner-centric model, using nonbinding letters of intent with Samsung Medison and Research Laboratories to accelerate innovation. The company completed a restructuring transaction with TCW Asset Management, converting $40 million of debt into preferred equity. Management is not providing fiscal 2027 guidance due to geopolitical uncertainty. The company expects approximately $15 million in additional annualised cost improvements and has secured a covenant holiday through December 2027.

Yahoo Finance
Aug 20th, 2026
Accuray posts $402M revenue, achieves $20M cost savings amid 12% annual decline

Accuray reported Q4 2026 net revenue of $100.9 million, down 21% year-over-year, with full-year revenue at $402 million, down 12%. Product revenue fell 42% in Q4 to $40.8 million, whilst service revenue rose 6% to $60.1 million. The medical device company exceeded its transformation cost-saving target, achieving over $20 million in savings versus a $12 million goal. Q4 gross margin improved to 34.8% from 30.6% in the prior year. Accuray strengthened its balance sheet through a transaction with TCW, including debt conversion and a $15 million cash investment. The company ended Q4 with $48.8 million in cash and $313 million in order backlog. Full-year adjusted EBITDA was $10.6 million, down from $28.3 million in the prior year.